Ace inhibitors and angiotensin II antagonists in acute coronary syndrome;Ace-inhibitori I antagonisti receptora ZA angiotenzin II U akutnom koronarnom sindromu

Acta Medica Croatica

Volumn 58, Issue 2, 2004, Pages 129-134

  Miličić, Davor ^a,b  

^a KBC Zagreb   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

ACE inhibitors; Acute coronary syndrome; Angiotensin II receptor blockers

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; VALSARTAN;

ATHEROSCLEROSIS; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EVIDENCE BASED MEDICINE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; MORTALITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; ST SEGMENT ELEVATION; UNSTABLE ANGINA PECTORIS;

ANGINA, UNSTABLE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; HUMANS; MYOCARDIAL INFARCTION; RECEPTORS, ANGIOTENSIN;

EID: 2542471650     PISSN: 13300164     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Dzau VJ. Circulating versus local renin-angiotensin system in cardiovascular homeostasis. Circulation 77 (Suppl I): I: 4-I-13, 1989.
2. Jin M, Wilhelm MJ, Lang RE i sur. The endogenous tissue renin-angiotensin systems: From molecular biology to therapy. Am J Med 1987; 84(Suppl 3A): 28-36.
3. Dzau VJ. Mechanism of protective effects of ACE inhibition on coronary artery disease. Eur Heart J 1998; 19(Suppl J): J2-J6.
4. Timmermans PB. Angiotensin II receptor antagonists: an emerging new class of cardiovascular therapeutics. Hypertension Research - Clinical & Experimental 1999; 22: 147-53.
5. Hanke CJ, O Brien T, Pritchard KA, Campbell WB. Inhibition of adrenal cell aldosterone synthesis by endogenous nitric oxide release. Hypertension 2000; 35: 324-8.
6. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res 1990; 66: 883-90..
7. Ertl G, Kloner RA, Alexander W i sur. Limitation of experimental myocardial ischemia. J Cardiovasc Pharmacol 1987; 9(Suppl 2): S9-S17.
8. van Gilst WH, Wijngaarden J, Scholtensw E i sur. Captopril induced increase in coronary flow: An SH-dependent effect on arachidonic acid metabolism. J Cardiovasc Pharmacol 1987; 9(Suppl 2): S31-S36.
9. Bartels L, Remme WJ, van der Ent M i sur. ACE inhibitors reduce myocardial ischemia through modulation of ischemia-induced catecholamine activation, experience with perindoprilat. J Am Coll Cardiol 1993; 21: 19A.
10. Schwartz JS, Bache RJ. Pharmacologic vasodilators in the coronary circulation. Circulation 1987; 75(Suppl 1): I-162-I-167.
11. Akhras F, Jackson G. The role of captopril as single therapy in hypertension and angina pectoris. Int J Cardiol 1991; 33: 259-66.
12. Stumpe KO, Overlack A on behalf of the Perindopril Therapeutic Safety Study Groups (PLUTS). A new trial of the efficiacy, tolerability and safety of angiotensin-converting enzyme inhibition in mild systemic hypertension with concomitant diseases and therapies. Am J Cardiol 1993; 71: 32E-37E.
13. Cleland JGF, Henderson E, McLenachan J i sur. Effect of captopril, and angiotensin-converting enzyme inhibitor, in patients with angina pectoris and heart failure. J Am Coll Cardiol 1991; 17: 733-9.
14. Heitzer T, Just H, Brochoff C i sur. Long-term nitroglycerin treatment is associated with supersensitivity to vasoconstrictors in men with stable coronary artery disease: prevention by concomitant treatment with captopril. J Am Coll Cardiol 1998; 31: 83-8.
15. Metelitsa WI, Lamas GA, Vaughan DE i sur. Left ventricular remodeling in the year after first anterior myocardial infarction: a quantitative analysis of contractile segment lengths and ventricular shape. J Am Coll Cardiol 1992; 19: 1136-44.
16. Dargie HJ, McAlpine J, Morton JJ. Neuroendocrine activation in acute myocardial infarction. J Cardiovasc Pharmacol 1987; 9(Suppl 2): S21-S24.
17. Yusuf S, Pepine CJ, Garces C i sur. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992; 340: 1173-8.
18. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-9.
19. Pfeffer MA, Braunwald E, Moye LA i sur. on behalf of the SAVE investigators: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327: 669-77.
20. Dana A, Walker M. Acute myocardial infarction. Extended review. J Roy Coll Phys London; 33: 131-40.
21. ACE Inhibitor Myocardial Infarction Collaborative Group: Indications for ACE inhibitors in the early treatment of acute myocardial infarction: Systematic overview of individual data from 100,000 patients in randomized trials. Circulation 1998; 97: 2202-12.
22. Pfeffer MA, Braunwald E, Moye LA i sur. Effect of captopril on mortality and mordibidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial The SAVE Investigators. N Engl J Med 1992; 327: 669-77.
23. The Acute Infarction Ramipril Efficiacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327: 669-77.
24. Kober L, Thorp-Pedersen C, Carlsen JE i sur. A clinical trial of the angiotensin-converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995; 333: 1670-6.
25. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-91.
26. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
27. The EUROPA investigators. Efficacy or perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised double-blind placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-8.
28. Domanski MJ, Exner DV, Borkow CB i sur. Effect of angiotensin converting enzyme inhibition on sudden death in patients following acute myocardial infarction. N Engl J Med 1999; 33: 598-604.
29. Havranek EP, Thomas I, Smith WB i sur. Dose-related beneficial long-term hemodynamic and clinical efficacy of irbersartan in heart failure. J Am Coll Cardiol 1999; 33: 1174-81.
30. Pitt B, Pool-Wilson PA i sur. Effects of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival ELITE II. Lancet 2000; 355: 1582-2587.
31. Pitt B, Segal R, Martinez FA i sur. Randomised trial of losartan versus captoprilin patients over 65 with heart failure. Lancet 1997; 349: 747-52.
32. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. New Engl J Med 2001; 345: 1667-75.
33. Dahlof B, Devreux RB, Kjeldsen SE i sur. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
34. Diskstein K, Kjekshus J and the OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360: 752-60.
35. Pfeffer MA, McMurray J, Leizorovicz A i sur. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. Am Heart J 2000; 140: 727-50.